Evaluation of repeated micropulse cyclophotocoagulation in patients with refractory glaucoma
| Autor: | I. E. Ioshin, A. I. Tolchinskaya, I. V. Maksimov, A. V. Rakova, O. M. Potapova, A. L. Illarionova, I. A. Romanova, E. V. Smirnova |
|---|---|
| Rok vydání: | 2021 |
| Zdroj: | National Journal glaucoma. 20:30-39 |
| ISSN: | 2311-6862 2078-4104 |
| DOI: | 10.53432/2078-4104-2021-20-3-30-39 |
| Popis: | PURPOSE. To evaluate the efficacy and safety of repeated micropulse transscleral cyclophotocoagulation (MP-TSCPC) in patients with previously operated refractory glaucoma.MATERIALS AND METHODS. We examined 89 patients aged 74.2±7.3 years with moderate (16), advanced (58) and terminal (15) stages of uncompensated primary openangle glaucoma (POAG) before and within 12 months after the first MP-TSCPC (SUPRA 810, “Quantel Medical”, France) using standard laser parameters — 100 J. Indications for repeated MP-TSCPC were determined for 23 patients in 3 (1 patient), 6 (14 patients), 9 (8 patients) months after the first procedure. Repeated MP-TSCPC was carried out with higher impact energy — 125 J.RESULTS. After the first procedure, the hypotensive effect was achieved in 66 (74.2%) patients with refractory glaucoma lasting up to 12 months of follow-up. Repeated MP-TSCPC in 23 patients reduced the IOP by 31.2% in moderate, 31.8% in advanced, and 22.9% in terminal stages (pCONCLUSION. Single and repeated micropulse TSCPC with laser energies of 100 J and 125 J is an effective and safe method of treating patients with refractory glaucoma. A single MP-TSCPC with laser energy of 100 J was effective in 66 (74.2%) patients by 12 months of observation, and single followed by repeated (laser energy of 125 J) — in 74 (83.1%) patients. It is possible to revise the basic parameters of the MP-TSCPC procedure from 100 to 125 J to achieve a longer and at the same time safe hypotensive effect in patients with refractory glaucoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|